LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

HomeStock ListAkebia Therapeutics Inc

Akebia Therapeutics Inc

Closed

Sector Healthcare

1.52 -0.65

Overview

Share price change

24h

Current

Min

1.47

Max

1.55

Key metrics

By Trading Economics

Income

15M

614K

Sales

14M

56M

P/E

Sector Avg

26.504

23.904

EPS

-0.08

Profit margin

1.093

Employees

167

EBITDA

14M

11M

Recommendations

By TipRanks

Rating Consensus

StrongBuy

12 Months Forecast

+235.57 upside

Dividends

By Dow Jones

Next earnings

6 May 2024

Market Stats

By TradingEconomics

Market Cap

-29M

312M

Previous open

2.17

Previous close

1.52

News Sentiment

By Acuity

41%

59%

81 / 274 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

Akebia Therapeutics Inc chart

Related News

28 Mar 2024, 10:30 UTC

Major Market Movers

Akebia Shares Rally Premarket After FDA Approves Vafseo

30 May 2023, 14:42 UTC

Major Market Movers

Akebia Therapeutics Shares Rise 13% After FDA Letter for Vadadustat

Peer Comparison

Price change

Akebia Therapeutics Inc forecast

Price Target

By TipRanks

235.57% upside

12 Months Forecast

Average 5 USD  235.57%

High 6 USD

Low 4 USD

Based on 3 Wall Street analysts offering 12 month price targets for Akebia Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

StrongBuy

3 ratings

3

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

1.5165 / 1.54 Support&Resistance

Short Team

Weak Bearish Evidence

Intermediate Term

Neutral Evidence

Long Term

Weak Bullish Evidence

Sentiment

By Acuity

81 / 274 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Akebia Therapeutics Inc

Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on producing medicines for people living with kidney disease. Its lead product candidate, vadadustat, is an oral therapy in development for the treatment of anemia due to chronic kidney disease (CKD). Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), designed to mimic the physiologic effect of altitude on oxygen availability. In addition, it has a commercial product, Auryxia (ferric citrate), which is marketed for two indications in the United States: the control of serum phosphorus levels in adult patients with dialysis-dependent (DD)-CKD or the hyperphosphatemia indication, and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis dependent (NDD)-CKD or the IDA indication. Its ferric citrate is also approved and marketed in Japan as an oral treatment for the improvement of hyperphosphatemia in patients with CKD.